Characteristics of the patient population (cohort study)
| Patient Characteristics . | Total Cohort (n = 612) . | t-MDS/t-AML (n = 22) . | ||
|---|---|---|---|---|
| HD . | NHL . | HD . | NHL . | |
| No. of patients | 218 | 394 | 11 | 11 |
| Age at transplant (y) | ||||
| Median (range) | 32.2 (13-66) | 44.6 (6-69) | 30.2 (19-45) | 46.4 (20-61) |
| <40 y | 165 (76%) | 132 (34%) | 9 (81%) | 3 (27%) |
| ≥40 y | 53 (24%) | 262 (66%) | 2 (19%) | 8 (73%) |
| Follow-up (y) | ||||
| Median (range) | 1.9 (0-10.2) | 1.6 (0-10.6) | — | — |
| Gender | ||||
| Males | 118 (54%) | 228 (58%) | 4 (36%) | 5 (46%) |
| Females | 100 (46%) | 166 (42%) | 7 (64%) | 6 (54%) |
| Source of stem cells | ||||
| BM | 31 (14%) | 30 (7%) | 2 (18%) | 1 (9%) |
| PSC/BM + PSC | 187 (86%) | 364 (93%) | 9 (88%) | 10 (91%) |
| Priming with VP-16 | 22 (10%) | 39 (10%) | 2 (18%) | 1 (9%) |
| Years to t-MDS/t-AML | ||||
| from primary diagnosis | — | — | 3.8 | 3.8 |
| from transplant | — | — | 0.9 | 2.4 |
| Vital status | ||||
| Died | 89 (41%) | 156 (40%) | 6 (55%) | 9 (82%) |
| Patient Characteristics . | Total Cohort (n = 612) . | t-MDS/t-AML (n = 22) . | ||
|---|---|---|---|---|
| HD . | NHL . | HD . | NHL . | |
| No. of patients | 218 | 394 | 11 | 11 |
| Age at transplant (y) | ||||
| Median (range) | 32.2 (13-66) | 44.6 (6-69) | 30.2 (19-45) | 46.4 (20-61) |
| <40 y | 165 (76%) | 132 (34%) | 9 (81%) | 3 (27%) |
| ≥40 y | 53 (24%) | 262 (66%) | 2 (19%) | 8 (73%) |
| Follow-up (y) | ||||
| Median (range) | 1.9 (0-10.2) | 1.6 (0-10.6) | — | — |
| Gender | ||||
| Males | 118 (54%) | 228 (58%) | 4 (36%) | 5 (46%) |
| Females | 100 (46%) | 166 (42%) | 7 (64%) | 6 (54%) |
| Source of stem cells | ||||
| BM | 31 (14%) | 30 (7%) | 2 (18%) | 1 (9%) |
| PSC/BM + PSC | 187 (86%) | 364 (93%) | 9 (88%) | 10 (91%) |
| Priming with VP-16 | 22 (10%) | 39 (10%) | 2 (18%) | 1 (9%) |
| Years to t-MDS/t-AML | ||||
| from primary diagnosis | — | — | 3.8 | 3.8 |
| from transplant | — | — | 0.9 | 2.4 |
| Vital status | ||||
| Died | 89 (41%) | 156 (40%) | 6 (55%) | 9 (82%) |
BM indicates bone marrow; HD, Hodgkin's disease; NHL, non-Hodgkin's lymphoma; PSC, peripheral stem cells; t-MDS/t-AML, morphologic therapy-related myelodysplasia and therapy-related acute myeloid leukemia.